Marty Makary Resigns from FDA
Analysis based on 10 articles · First reported May 12, 2026 · Last updated May 13, 2026
The resignation of Marty Makary from the United States — Food and Drug Administration and the appointment of Kyle Diamantas as acting commissioner could lead to shifts in regulatory policies concerning pharmaceuticals, particularly abortion pills like Mifepristone, and vaping products. This change in leadership may impact the stock prices of pharmaceutical and tobacco companies, depending on the new administration's stance on drug approvals and product regulations.
Dr. Marty Makary resigned as Commissioner of the United States — Food and Drug Administration on Tuesday, following widespread reports of his impending firing. President Donald Trump confirmed the resignation and appointed Kyle Diamantas as acting commissioner. Makary's departure was largely attributed to disagreements over his handling of the abortion pill Mifepristone, with pro-life advocates like Susan B. Anthony Pro-Life America and Senator Josh Hawley criticizing his policies. He also faced frustration from Donald Trump regarding his reluctance to approve flavored vaping products. Health and Human Services Secretary Robert F. Kennedy Jr. reportedly pushed for Makary's resignation. The event signals a potential shift in the United States — Food and Drug Administration's regulatory approach under new leadership.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard